This article provides a preview to the forthcoming articles in this issue, which are written by well-known and authoritative authors for the readers' pleasure and reference. This article hopes to provide a general overview that stimulates interest, better understanding, and continued joint commitment to the important subject of hypertension.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mcna.2016.08.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A prediction study on the occurrence risk of heart disease in older hypertensive patients based on machine learning.
BMC Geriatr
January 2025
Department of Cardiology, The Second Hospital & Clinical Medical School, Lanzhou University, No. 82 Cuiyingmen, Lanzhou, 730000, China.
Objective: Constructing a predictive model for the occurrence of heart disease in elderly hypertensive individuals, aiming to provide early risk identification.
Methods: A total of 934 participants aged 60 and above from the China Health and Retirement Longitudinal Study with a 7-year follow-up (2011-2018) were included. Machine learning methods (logistic regression, XGBoost, DNN) were employed to build a model predicting heart disease risk in hypertensive patients.
Integrative bioinformatics approach identifies novel drug targets for hyperaldosteronism, with a focus on SHMT1 as a promising therapeutic candidate.
Sci Rep
January 2025
Department of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88, Jiefang Road, Shangcheng District, Hangzhou, 310000, Zhejiang Province, China.
Primary aldosteronism (PA), characterized by autonomous aldosterone overproduction, is a major cause of secondary hypertension with significant cardiovascular complications. Current treatments mainly focus on symptom management rather than addressing underlying mechanisms. This study aims to discover novel therapeutic targets for PA using integrated bioinformatics and experimental validation approaches.
View Article and Find Full Text PDFPredictors of Outcome in Patients with Presumed Reversible Cerebral Vasoconstriction Syndrome (RCVS).
J Stroke Cerebrovasc Dis
January 2025
Department of Neurosurgery, University of Illinois Chicago, Chicago, IL. Electronic address:
Introduction: Reversible cerebral vasoconstriction syndrome (RCVS) is thought to be benign by nature, but a proportion of patients still suffer from neurological deficits on follow-up.
Objective: To understand what factors may influence a patient's recovery from RCVS.
Methods: The Clinical Research Data Warehouse at this institution was employed to search the medical records for patients with diagnosis and treatment of RCVS (2010-2021).
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Lancet
January 2025
Department of Diagnostic and Interventional Radiology, University of Pisa School of Medicine, Pisa, Italy.
Background: Transarterial chemoembolisation (TACE) is standard of care for patients with unresectable hepatocellular carcinoma that is amenable to embolisation; however, median progression-free survival is still approximately 7 months. We aimed to assess whether adding durvalumab, with or without bevacizumab, might improve progression-free survival.
Methods: In this multiregional, randomised, double-blind, placebo-controlled, phase 3 study (EMERALD-1), adults aged 18 years or older with unresectable hepatocellular carcinoma amenable to embolisation, an Eastern Cooperative Oncology Group performance status of 0 or 1 at enrolment, and at least one measurable intrahepatic lesion per modified Response Evaluation Criteria in Solid Tumours (RECIST) were enrolled at 157 medical sites including research centres and general and specialist hospitals in 18 countries.
The Clinical and Economic Burden of Chronic Kidney Disease in Poland: Inside Patient-Level Microsimulation Modelling of CKD.
J Clin Med
December 2024
Department of Nephrology, Hypertension, Transplantation and Internal Medicine, Central University Hospital, Medical University of Lodz, 90-419 Lodz, Poland.
Chronic kidney disease (CKD) is associated with increased annual costs, with the highest costs attributable to renal replacement therapy (RRT). These costs will rise as prevalence increases. Therefore, forecasting the future prevalence and economic burden of CKD, particularly in underdiagnosed populations, may provide valuable insights to policymakers looking at strategies to implement interventions to delay CKD progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!